903899-13-8 | Page 2 of 2 | Pyridine-derivatives

Fabritius, Charles-Henry’s team published research in Bioorganic & Medicinal Chemistry Letters in 26 | CAS: 903899-13-8

Bioorganic & Medicinal Chemistry Letters published new progress about 903899-13-8. 903899-13-8 belongs to pyridine-derivatives, auxiliary class Pyridine,Boronic acid and ester,Alcohol,Boronic Acids,Boronic acid and ester, name is (6-Hydroxypyridin-3-yl)boronic acid, and the molecular formula is C5H6BNO3, Synthetic Route of 903899-13-8.

Fabritius, Charles-Henry published the artcile1-Sulfonyl-6-piperazinyl-7-azaindoles as potent and pseudo-selective 5-HT₆ receptor antagonists, Synthetic Route of 903899-13-8, the publication is Bioorganic & Medicinal Chemistry Letters (2016), 26(11), 2610-2615, database is CAplus and MEDLINE.

A series of 1-sulfonyl-6-piperazinyl-7-azaindoles, showing strong antagonistic activity to 5-HT₆ receptor (5-HT₆R) was synthesized and characterized. The series was optimized to reduce activity on D₂ receptor. Based on the selectivity against this off-target and the anal. of the ADME-tox profile, compound 1c was selected for in vivo efficacy assessment, which demonstrated procognitive effects as shown in reversal of scopolamine induced amnesia in an elevated plus maze test in mice. Compound 3, the demethylated version of compound 1c, was profiled against a panel of 106 receptors, channels and transporters, indicating only D₃ receptor as a major off-target. Compound 3 has been selected for this study over compound 1c because of the higher 5-HT₆R/D₂R binding ratio. These results have defined a new direction for the design of our pseudo-selective 5-HT₆R antagonists.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Aggarwal, Anup’s team published research in Cell (Cambridge, MA, United States) in 170 | CAS: 903899-13-8

Cell (Cambridge, MA, United States) published new progress about 903899-13-8. 903899-13-8 belongs to pyridine-derivatives, auxiliary class Pyridine,Boronic acid and ester,Alcohol,Boronic Acids,Boronic acid and ester, name is (6-Hydroxypyridin-3-yl)boronic acid, and the molecular formula is C5H6BNO3, Quality Control of 903899-13-8.

Aggarwal, Anup published the artcileDevelopment of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13, Quality Control of 903899-13-8, the publication is Cell (Cambridge, MA, United States) (2017), 170(2), 249-259.e25, database is CAplus and MEDLINE.

Widespread resistance to first-line TB drugs is a major problem that will likely only be resolved through the development of new drugs with novel mechanisms of action. The authors have used structure-guided methods to develop a lead mol. that targets the thioesterase activity of polyketide synthase Pks13, an essential enzyme that forms mycolic acids, required for the cell wall of Mycobacterium tuberculosis. The authors’ lead, TAM16, is a benzofuran class inhibitor of Pks13 with highly potent in vitro bactericidal activity against drug-susceptible and drug-resistant clin. isolates of M. tuberculosis. In multiple mouse models of TB infection, TAM16 showed in vivo efficacy equal to the first-line TB drug isoniazid, both as a monotherapy and in combination therapy with rifampicin. TAM16 has excellent pharmacol. and safety profiles, and the frequency of resistance for TAM16 is â?00-fold lower than INH, suggesting that it can be developed as a new antitubercular aimed at the acute infection.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Rao, Ashwin U.’s team published research in Bioorganic & Medicinal Chemistry Letters in 19 | CAS: 903899-13-8

Rao, Ashwin U. published the artcileSynthesis and structure-activity relationships of 2-(1,4′-bipiperidin-1′-yl)thiazolopyridines as H₃ receptor antagonists, Safety of (6-Hydroxypyridin-3-yl)boronic acid, the publication is Bioorganic & Medicinal Chemistry Letters (2009), 19(21), 6176-6180, database is CAplus and MEDLINE.

A series of 2-(1,4′-bipiperidin-1′-yl)thiazolopyridines I (X = N, Y = CH; X = CH, Y = N; R = H, H₂N, CN, Cl, MeCONH, 4-NCC₆H₄, 2-fluoro-3-pyridyl, 5-pyrimidyl, etc.) was synthesized and evaluated as a new lead of non-imidazole histamine H₃ receptor antagonists. Introduction of diversity at the 6-position of the pyridine ring was designed to enhance in vitro potency and decrease hERG activity. The structure-activity relationships for these new thiazolopyridine antagonists are discussed.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Kim, Junwon’s team published research in Bioorganic & Medicinal Chemistry Letters in 24 | CAS: 903899-13-8

Kim, Junwon published the artcileSerendipitous discovery of 2-((phenylsulfonyl)methyl)-thieno[3,2-d]pyrimidine derivatives as novel HIV-1 replication inhibitors, Safety of (6-Hydroxypyridin-3-yl)boronic acid, the publication is Bioorganic & Medicinal Chemistry Letters (2014), 24(23), 5473-5477, database is CAplus and MEDLINE.

The authors identified a novel class of 2-[(phenylsulfonyl)methyl]thieno[3,2-d]pyrimidine compounds as potent HIV-1 replication inhibitors serendipitously during the process of evaluation of triazolothienopyrimidine (TTPM) compounds Herein, the authors report a synthesis and biol. evaluation of 2-[(phenylsulfonyl)methyl]thieno[3,2-d]pyrimidine compounds using a cell-based full replication assay to identify thienopyrimidine derivatives which could be further utilized as viable lead compounds The synthesis of the target compounds was achieved by a reaction of (chloro)[[(aryl)sulfonyl]methyl]thieno[3,2-d]pyrimidine with boronic acids, amines, phenol derivative

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Lu, Xiao’s team published research in European Journal of Organic Chemistry in 2018 | CAS: 903899-13-8

European Journal of Organic Chemistry published new progress about 903899-13-8. 903899-13-8 belongs to pyridine-derivatives, auxiliary class Pyridine,Boronic acid and ester,Alcohol,Boronic Acids,Boronic acid and ester, name is (6-Hydroxypyridin-3-yl)boronic acid, and the molecular formula is C5H6BNO3, Recommanded Product: (6-Hydroxypyridin-3-yl)boronic acid.

Lu, Xiao published the artcileAcid-Promoted Cascade Reaction of N-(4-Chloroquinolin-3-yl)carbamates with Amines: One-Pot Assembly of Imidazo[4,5-c]quinolin-2-ones, Recommanded Product: (6-Hydroxypyridin-3-yl)boronic acid, the publication is European Journal of Organic Chemistry (2018), 2018(13), 1572-1580, database is CAplus and MEDLINE.

An acid-promoted cascade reaction of N-(4-chloroquinolin-3-yl)carbamates with amines is described. This method achieves the formation of two new C-N bonds through an intermol. amination/intramol. cyclization reaction sequence. In combination with a subsequent Suzuki coupling reaction, this three-component telescopic procedure provides rapid access to various bioactive imidazo[4,5-c]quinolin-2-one derivatives

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Allegretti, Paul A.’s team published research in Bioorganic & Medicinal Chemistry in 28 | CAS: 903899-13-8

Bioorganic & Medicinal Chemistry published new progress about 903899-13-8. 903899-13-8 belongs to pyridine-derivatives, auxiliary class Pyridine,Boronic acid and ester,Alcohol,Boronic Acids,Boronic acid and ester, name is (6-Hydroxypyridin-3-yl)boronic acid, and the molecular formula is C5H6BNO3, Recommanded Product: (6-Hydroxypyridin-3-yl)boronic acid.

Allegretti, Paul A. published the artcileGeneration of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization, Recommanded Product: (6-Hydroxypyridin-3-yl)boronic acid, the publication is Bioorganic & Medicinal Chemistry (2020), 28(1), 115193, database is CAplus and MEDLINE.

Small mol. stimulation of β-cell regeneration has emerged as a promising therapeutic strategy for diabetes. Although chem. inhibition of dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) is sufficient to enhance β-cell replication, current lead compounds have inadequate cellular potency for in vivo application. Herein, we report the clin. stage anti-cancer kinase inhibitor OTS167 as a structurally novel, remarkably potent DYRK1A inhibitor and inducer of human β-cell replication. Unfortunately, OTS167’s target promiscuity and cytotoxicity curtails utility. To tailor kinase selectivity towards DYRK1A and reduce cytotoxicity we designed a library of fifty-one OTS167 derivatives based upon a modeled structure of the DYRK1A-OTS167 complex. Indeed, derivative characterization yielded several leads with exceptional DYRK1A inhibition and human β-cell replication promoting potencies but substantially reduced cytotoxicity. These compounds are the most potent human β-cell replication-promoting compounds yet described and exemplify the potential to purposefully leverage off-target activities of advanced stage compounds for a desired application.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Wu, Wen-Lian’s team published research in Bioorganic & Medicinal Chemistry Letters in 16 | CAS: 903899-13-8

Wu, Wen-Lian published the artcileDesign and synthesis of orally efficacious benzimidazoles as melanin-concentrating hormone receptor 1 antagonists, Safety of (6-Hydroxypyridin-3-yl)boronic acid, the publication is Bioorganic & Medicinal Chemistry Letters (2006), 16(14), 3674-3678, database is CAplus and MEDLINE.

Biaryl urea lead compound I was discovered earlier in an MCH antagonist program. Novel benzimidazole analogs with increased chem. stability, devoid of the potential carcinogenic liability associated with a biarylamine moiety, were synthesized and evaluated to be potent MCH R1 antagonists. Two compounds in this series have demonstrated in vivo efficacy in a rodent obesity model.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem